Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, PR China.
Laboratory of Cerebrovascular Disease, Nanjing Medical University, Nanjing, PR China.
J Pathol. 2018 Feb;244(2):176-188. doi: 10.1002/path.4999. Epub 2017 Dec 29.
Mechanisms underlying functional recovery after stroke are little known, and effective drug intervention during the delayed stage is desirable. One potential drug target, the protein-protein interaction between neuronal nitric oxide synthase (nNOS) and postsynaptic density protein 95 (PSD-95), is critical to acute ischaemic damage and neurogenesis. We show that nNOS-PSD-95 dissociation induced by microinjection of a recombinant fusion protein, Tat-nNOS-N , or systemic administration of a small-molecule, ZL006, from day 4 to day 10 after photothrombotic ischaemia in mice reduced excessive tonic inhibition in the peri-infarct cortex and ameliorated motor functional outcome. We also demonstrated improved neuroplasticity including increased dendrite spine density and synaptogenesis after reducing excessive tonic inhibition by nNOS-PSD-95 dissociation. Levels of gamma-aminobutyric acid (GABA) and GABA transporter-3/4 (GAT-3/4) are increased in the reactive astrocytes in the peri-infarct cortex. The GAT-3/4-selective antagonist SNAP-5114 reduced tonic inhibition and promoted function recovery, suggesting that increased tonic inhibition in the peri-infarct cortex was due to GABA release from reversed GAT-3/4 in reactive astrocytes. Treatments with Tat-nNOS-N or ZL006 after ischaemia inhibited astrocyte activation and GABA production, prevented the reversal of GAT-3/4, and consequently decreased excessive tonic inhibition and ameliorated functional outcome. The underlying molecular mechanisms were associated with epigenetic inhibition of glutamic acid decarboxylase 67 and monoamine oxidase B expression through reduced NO production. The nNOS-PSD-95 interaction is thus a potential target for functional restoration after stroke and ZL006, a small molecule inhibitor of this interaction, is a promising pharmacological lead compound. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
脑卒中后功能恢复的机制尚不清楚,延迟期有效的药物干预是可取的。神经元型一氧化氮合酶(nNOS)与突触后密度蛋白 95(PSD-95)之间的蛋白-蛋白相互作用是一种潜在的药物靶点,对于急性缺血损伤和神经发生至关重要。我们发现,在光血栓性缺血后 4 至 10 天,通过微注射重组融合蛋白 Tat-nNOS-N 或全身给予小分子 ZL006,诱导 nNOS-PSD-95 解离,可减少梗死周边皮层过度紧张性抑制,改善运动功能。我们还证明,通过减少 nNOS-PSD-95 解离引起的过度紧张性抑制,可改善神经可塑性,包括增加树突棘密度和突触形成。在梗死周边皮层的反应性星形胶质细胞中,γ-氨基丁酸(GABA)和 GABA 转运体-3/4(GAT-3/4)的水平增加。GAT-3/4 选择性拮抗剂 SNAP-5114 减少紧张性抑制并促进功能恢复,表明梗死周边皮层中过度紧张性抑制是由于 GABA 从反应性星形胶质细胞中的逆向 GAT-3/4 释放引起的。缺血后用 Tat-nNOS-N 或 ZL006 治疗可抑制星形胶质细胞激活和 GABA 产生,防止 GAT-3/4 的逆转,从而减少过度紧张性抑制并改善功能结局。潜在的分子机制与通过减少 NO 产生,对谷氨酸脱羧酶 67 和单胺氧化酶 B 表达的表观遗传抑制有关。因此,nNOS-PSD-95 相互作用是脑卒中后功能恢复的潜在靶点,ZL006 是该相互作用的小分子抑制剂,是一种有前途的药理学先导化合物。